Interventional Cardiology Devices Market Top Companies Study - Medtronic (US), Boston Scientific Corporation (US), Abbott (US), Edward Lifescinces Corporation (US), Cardinal Health (US).

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Interventional Cardiology Devices Market- (By Product (Angioplasty Balloons (Old/Normal Balloons, Drug-eluting Balloons, Cutting and Scoring Balloons), Angioplasty Stents (Drug-eluting Stents, Bare-metal Stents, Bioabsorbable Stents), Structural Heart Devics (Aortic Valve Therapy Devices, Other Therapy Devices (Mitral valve, pulmonary valve and tricuspid valve and left atrial appendage therapy devices)), Catheters (Angiography Catheters, Guiding Catheters, IVUS/OCT Catheters), Plaque Modification Devices (Atherectomy Devices, Thrombectomy Devices), Hemodynamic Flow Alteration Devices (Embolic Protection Devices, Chronic Total Occlusion Devices), Other Devices (Guidewires, Vascular Closure Devices, Introducer Sheaths, Hemostasis Valves, Balloon Inflation Devices)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Interventional Cardiology Devices Market is valued at USD 18.84 Bn in 2023, and it is expected to reach USD 33.91 Bn by the year 2031, with a CAGR of 7.75% during a forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2012

Interventional cardiology devices are advanced medical instruments utilized in the diagnosis and treatment of cardiovascular conditions through minimally invasive, catheter-based procedures. These devices play a pivotal role in interventional cardiology, offering alternatives to traditional open-heart surgeries and enabling more precise, efficient patient care.

Recent epidemiological data indicate that heart attacks and strokes are responsible for more than 80% of cardiovascular-related deaths, with a considerable proportion occurring in individuals under the age of 70. Key behavioral risk factors-such as unhealthy dietary habits, tobacco use, physical inactivity, and excessive alcohol intake-continue to contribute significantly to the global burden of cardiovascular disease. Additionally, conditions such as obesity and hypertension are strongly correlated with increased cardiovascular risk and are expected to drive sustained demand for interventional cardiology solutions.

The market is further bolstered by the growing incidence of chronic conditions such as diabetes and high blood pressure, both of which exacerbate cardiovascular complications. Diabetes, in particular, is known to impair vascular function due to prolonged high blood glucose levels, increasing the likelihood of coronary artery disease. As a result, the demand for interventional cardiology devices is anticipated to grow steadily throughout the forecast period, supported by the rising prevalence of these risk factors and the ongoing emphasis on early diagnosis and minimally invasive interventions.

List of Prominent Players in the Interventional Cardiology Devices Market:
• Medtronic (US),
• Boston Scientific Corporation (US),
• Abbott (US),
• Edward Lifescinces Corporation (US),
• Cardinal Health (US),
• iVascular (Spain),
• Becton, Dickinson, and Company (US),
• B. Braun Melsungen (Germany),
• Terumo Corporation (Japan),
• Biosensors International Group (Singapore),
• BIOTRONIK SE & Co. KG (Germany).

Market Dynamics:
Drivers-
Cardiovascular diseases, such as valvular defects and atrial stenosis, are widespread in developing countries like China, India, and Brazil, driving a significant demand for interventional cardiology devices. To meet this growing need, leading medical device manufacturers are heavily investing in research and development to create and launch innovative products tailored to these markets. Additionally, key industry players are forming strategic collaborations to conduct various clinical trials on interventional devices. The market is also expected to see further growth as regulatory bodies in developing countries increasingly approve these devices from domestic manufacturers.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Challenges:
The interventional cardiology device market experienced substantial disruption in 2020 as a result of the COVID-19 pandemic, which led to the widespread postponement of elective surgical procedures. During this period, healthcare systems globally redirected resources to address the surge in COVID-19 cases, causing delays in the treatment of structural and coronary heart diseases. However, by 2021, the resumption of elective and interventional surgeries-particularly coronary procedures-gained momentum across multiple regions. The post-pandemic healthcare environment has further supported the adoption of interventional therapies, as their minimally invasive nature aligns with enhanced infection control measures, thereby contributing to sustained market growth.

Regional Trends:
North America is expected to maintain the largest share of revenue in the interventional cardiology device market. This leadership position is primarily driven by the region's high prevalence of coronary heart disease and the strategic focus of key industry players on the development and commercialization of advanced technologies. The increasing rate of diagnosis and treatment of coronary conditions further supports market expansion. In addition, Europe accounted for a significant portion of the market in 2021, supported by the widespread availability and affordability of interventional cardiology devices in the region.

Recent Developments:
• In Feb 2023, Abbott agreed to buy Cardiovascular Systems (CSI), a business that makes medical devices, in a deal worth about $890 Bn. Interventional treatment devices for people with peripheral and coronary artery disease were made by CSI and sold to patients. The devices were made for atherectomy, which is a minimally invasive way to treat plaque buildup in the vessels that can stop blood flow.
• In March 2021, The multinational medical technology company Medtronic recently declared the commercialization of their Chameleon Percutaneous Transluminal Angioplasty (PTA) balloon catheter in various nations, including Italy, Portugal, South Africa, and Turkey. The gadget facilitates the administration of diagnostic or therapeutic fluids by means of the integrated injection port located near the balloon.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2012

Segmentation of Interventional Cardiology Devices Market-
By Product
• Angioplasty Balloons
o Old/Normal Balloons
o Drug-eluting Balloons
o Cutting and Scoring Balloons
• Angioplasty Stents
o Drug-eluting Stents
o Bare-metal Stents
o Bioabsorbable Stents
• Structural Heart Devics
o Aortic Valve Therapy Devices
o Other Therapy Devices (Mitral valve, pulmonary valve and tricuspid valve and left atrial appendage therapy devices)
• Catheters
o Angiography Catheters
o Guiding Catheters
o IVUS/OCT Catheters
• Plaque Modification Devices
o Atherectomy Devices
o Thrombectomy Devices
• Hemodynamic Flow Alteration Devices
o Embolic Protection Devices
o Chronic Total Occlusion Devices
• Other Devices
o Guidewires
o Vascular Closure Devices
o Introducer Sheaths
o Hemostasis Valves
o Balloon Inflation Devices
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/interventional-cardiology-devices-market/2012

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.